이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Carna Biosciences 관리

관리 기준 확인 2/4

Carna Biosciences' CEO는 Kohichiro Yoshino, Apr2003 에 임명되었습니다 의 임기는 21.17 년입니다. 는 ¥ 126.55M 가치에 해당하는 회사 주식의 1.85% 직접 소유합니다. 126.55M. 경영진과 이사회의 평균 재임 기간은 각각 12.3 년과 6.3 년입니다.

주요 정보

Kohichiro Yoshino

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	21.2yrs
CEO 소유권	1.8%
경영진 평균 재임 기간	12.3yrs
이사회 평균 재임 기간	6.3yrs

최근 관리 업데이트

Recent updates

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

CEO

Kohichiro Yoshino (75 yo)

21.2yrs

테뉴어

Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kohichiro Yoshino	CEO, President & Representative Director	21.2yrs	데이터 없음	1.85% ¥ 130.2m
Emi Yamamoto	GM of Business Mgt.	8.8yrs	데이터 없음	0.30% ¥ 21.3m
Masaaki Sawa	GM of Research & Development Division	no data	데이터 없음	0.59% ¥ 41.3m
Norio Aikawa	Head of Drug Discovery & Support Business	15.9yrs	데이터 없음	0.57% ¥ 39.8m
Akinori Arimura	GM of Clinical Development	5.3yrs	데이터 없음	0.091% ¥ 6.4m

12.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 4572 의 관리팀은 노련하고 경험 (평균 재직 기간 12.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kohichiro Yoshino	CEO, President & Representative Director	21.2yrs	데이터 없음	1.85% ¥ 130.2m
Emi Yamamoto	GM of Business Mgt.	8.3yrs	데이터 없음	0.30% ¥ 21.3m
Masaaki Sawa	GM of Research & Development Division	9.3yrs	데이터 없음	0.59% ¥ 41.3m
Norio Aikawa	Head of Drug Discovery & Support Business	20.3yrs	데이터 없음	0.57% ¥ 39.8m
Akinori Arimura	GM of Clinical Development	1.3yrs	데이터 없음	0.091% ¥ 6.4m
Tsuguo Ogasawara	Independent Outside Director	4.4yrs	데이터 없음	0.028% ¥ 1.9m
Atsuo Arita	Independent Outside Director	4.4yrs	데이터 없음	0.044% ¥ 3.1m
Teruo Takayanagi	Independent Outside Director	9.3yrs	데이터 없음	0.0061% ¥ 428.7k
Takao Matsui	Independent Outside Director	4.4yrs	데이터 없음	데이터 없음
Kaoru Suzuki	Independent Outside Director	less than a year	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

75yo

평균 연령

경험이 풍부한 이사회: 4572 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.

Carna Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령